Stryker Corporation $SYK Shares Sold by Erste Asset Management GmbH

Erste Asset Management GmbH decreased its holdings in shares of Stryker Corporation (NYSE:SYK) by 13.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 127,941 shares of the medical technology company’s stock after selling 19,611 shares during the period. Erste Asset Management GmbH’s holdings in Stryker were worth $45,358,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Godfrey Financial Associates Inc. acquired a new stake in shares of Stryker during the fourth quarter worth about $26,000. United Financial Planning Group LLC acquired a new stake in shares of Stryker during the third quarter worth about $27,000. Strive Asset Management LLC acquired a new stake in Stryker in the third quarter valued at about $30,000. CGC Financial Services LLC acquired a new stake in Stryker in the fourth quarter valued at about $29,000. Finally, ANTIPODES PARTNERS Ltd acquired a new stake in Stryker in the third quarter valued at about $34,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Price Performance

SYK stock opened at $305.71 on Monday. The firm has a 50 day moving average of $318.43 and a 200-day moving average of $345.76. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $404.87. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The company has a market cap of $117.20 billion, a price-to-earnings ratio of 35.38, a PEG ratio of 1.93 and a beta of 0.78.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. During the same quarter in the previous year, the business posted $2.84 earnings per share. Stryker’s revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities analysts expect that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is presently 40.74%.

Insider Activity

In other news, VP M Kathryn Fink sold 3,500 shares of Stryker stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.45, for a total transaction of $992,075.00. Following the completion of the sale, the vice president directly owned 177 shares in the company, valued at approximately $50,170.65. This trade represents a 95.19% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the sale, the vice president owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 323,264 shares of company stock worth $100,659,489. Company insiders own 4.60% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on SYK. Sanford C. Bernstein set a $410.00 price objective on shares of Stryker in a research report on Friday, May 1st. Weiss Ratings downgraded shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 4th. Truist Financial restated a “hold” rating and issued a $330.00 price objective (down from $380.00) on shares of Stryker in a research report on Monday, May 4th. Wells Fargo & Company reduced their price objective on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. Finally, Needham & Company LLC reduced their price target on shares of Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Sixteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $395.33.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.